HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.

HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.

Total
0
Shares
Related Posts